861064-05-3

Upstream product

• 17849-38-6 2-Chlorobenzyl alcohol 
• 79-08-3 bromoacetic acid 
• 159448-28-9 (2-chloro-benzyloxy)-acetic acid ethyl ester 
• 611-19-8 1-chloro-2-(chloromethyl)benzene 

Downstream Products

• 1254506-98-3 C₉H₈Cl₂O₂ 
• 1355054-92-0 (+/-)-(2-{2-[2-(2-chlorobenzyloxy)acetyl]-1,2,3,4-tetrahydroisoquinolin-1-yl}-4-fluorophenoxy)acetic acid 

Relevant academic research and scientific papers

Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) to Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo

Nucleotide-binding oligomerization domain-like receptors (NLRs) are intracellular sensors of pathogen-Associated molecular patterns (PAMPs) and damage-Associated molecular patterns (DAMPs). Previously, we reported nucleotide-binding oligomerization domain-containing protein 1 (NOD1) antagonists (11, 12) and a NOD2 antagonist (9) that sensitized docetaxel (DTX) or paclitaxel (PTX) treatment for breast or lung cancer. In this article, we describe for the first time a 1,4-benzodiazepine-2,5-dione (BZD) derivative (26bh) that acts as a dual NOD1/NOD2 antagonist and inhibits both nuclear factor B (NF-B) and mitogen-Activated protein kinase (MAPK) inflammatory signaling, thereby sensitizing PTX to suppress Lewis lung carcinoma (LLC) growth. After investigation of the compound's cytotoxicity, a systematic structure-Activity relationship (SAR) was completed and revealed several key factors that were necessary to maintain antagonistic ability. This study establishes the possibility for using adjuvant treatment to combat cancer by antagonizing both NOD1 and NOD2 signaling.

DIALKYL ETHER DELIVERY AGENTS

The present invention provides dialkyl ether compounds and pharmaceutically acceptable salts thereof, compositions containing the same and one or more active agents, and methods of administering active agents with the same.